Traders sold shares of Gilead Sciences, Inc. (NASDAQ:GILD) on strength during trading hours on Tuesday. $45.02 million flowed into the stock on the tick-up and $86.47 million flowed out of the stock on the tick-down, for a money net flow of $41.45 million out of the stock. Of all companies tracked, Gilead Sciences had the 0th highest net out-flow for the day. Gilead Sciences traded up $0.74 for the day and closed at $73.34

A number of equities analysts have issued reports on GILD shares. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $74.34 target price on the stock. in a research report on Thursday, May 11th. Gabelli reaffirmed a “buy” rating and issued a $85.00 target price on shares of Gilead Sciences in a research report on Wednesday, May 3rd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $87.00 target price on shares of Gilead Sciences in a research report on Wednesday, May 3rd. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $76.00 target price on the stock in a research report on Tuesday, May 2nd. Finally, Deutsche Bank AG started coverage on Gilead Sciences in a research report on Friday, June 23rd. They issued a “buy” rating and a $79.00 target price on the stock. Eleven investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $80.64.

The firm’s 50-day moving average is $72.76 and its 200 day moving average is $68.82. The stock has a market capitalization of $96.30 billion, a price-to-earnings ratio of 8.01 and a beta of 1.21.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.45. The business had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. Gilead Sciences’s revenue for the quarter was down 8.2% compared to the same quarter last year. During the same period last year, the company earned $3.08 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post $8.74 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.82%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s dividend payout ratio is currently 22.58%.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the sale, the insider now directly owns 3,199,969 shares in the company, valued at approximately $227,197,799. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.06, for a total value of $355,300.00. Following the sale, the executive vice president now owns 102,988 shares of the company’s stock, valued at $7,318,327.28. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 206,666 shares of company stock valued at $15,223,184. 1.30% of the stock is owned by corporate insiders.

A number of hedge funds have recently modified their holdings of GILD. Rockland Trust Co. increased its stake in shares of Gilead Sciences by 16.7% in the first quarter. Rockland Trust Co. now owns 178,245 shares of the biopharmaceutical company’s stock worth $12,106,000 after buying an additional 25,551 shares during the last quarter. Linscomb & Williams Inc. increased its stake in shares of Gilead Sciences by 3.0% in the first quarter. Linscomb & Williams Inc. now owns 5,275 shares of the biopharmaceutical company’s stock worth $358,000 after buying an additional 154 shares during the last quarter. Berkshire Asset Management LLC PA acquired a new stake in shares of Gilead Sciences during the first quarter worth $270,000. Sigma Planning Corp increased its stake in shares of Gilead Sciences by 7.7% in the first quarter. Sigma Planning Corp now owns 40,168 shares of the biopharmaceutical company’s stock worth $2,728,000 after buying an additional 2,889 shares during the last quarter. Finally, Hollencrest Securities LLC increased its stake in shares of Gilead Sciences by 119.8% in the first quarter. Hollencrest Securities LLC now owns 7,723 shares of the biopharmaceutical company’s stock worth $525,000 after buying an additional 4,210 shares during the last quarter. Hedge funds and other institutional investors own 74.02% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Traders Sell Shares of Gilead Sciences, Inc. (GILD) on Strength (GILD)” was reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/08/24/traders-sell-shares-of-gilead-sciences-inc-gild-on-strength-gild-4.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.